Impact News +++ Milliarden-Deal: Accenture übernimmt Netzwerkanalyse-Spezialisten Ookla (Heise) +++ ZIFF DAVIS Aktie -10,50%

BOSTON SCIENTIFIC Aktie

>Aktienkurs

63.6 EUR -2.5% (TradegateBSX)

Ask: 63.6 EUR / 60 Stück

Bid: 63.4 EUR / 60 Stück

Tagesumsatz: 1042 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

Aktie über LYNX handeln

Intraday

1 Jahr

>Performance

1 Woche: -0,6%

1 Monat: -17,8%

3 Monate: -24,8%

6 Monate: -30,6%

1 Jahr: -35,8%

laufendes Jahr: -21,9%

>BOSTON SCIENTIFIC Aktie

Name:

BOSTON SCIENTIFIC DL-,01

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US1011371077 / 884113

Symbol/ Ticker:

BSX (Frankfurt) / BSX (NYSE)

Kürzel:

FRA:BSX, ETR:BSX, BSX:GR, NYSE:BSX

Index:

S&P500

Webseite:

http://www.bostonscientif..

Profil:

Boston Scientific Corporation develops, manufactures, and markets medical devices for interventional medical procedures worldwide. It operates through two primary segments: MedSurg, encompassing Endos..
>Volltext..

Marktkapitalisierung:

97547.34 Mio. EUR

Unternehmenswert:

106272.18 Mio. EUR

Umsatz:

17314.17 Mio. EUR

EBITDA:

4691 Mio. EUR

Nettogewinn:

2499.45 Mio. EUR

Gewinn je Aktie:

1.69 EUR

Schulden:

10325.54 Mio. EUR

Liquide Mittel:

1763.76 Mio. EUR

Operativer Cashflow:

3910.46 Mio. EUR

Bargeldquote:

0.38

Umsatzwachstum:

5.66%

Gewinnwachstum:

37.85%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

1 Insider verkaufte innerhalb der letzten 30 Tage Aktien im Wert von 15.043.394 USD.

Suchwörter:

BOSTON SCIENTIFIC

Letzte Datenerhebung:

04.03.26

>Kennzahlen

Aktien/ Unternehmen:

Aktien: 1483.89 Mio. St.

Frei handelbar: 99.63%

Leerverk. Aktien: 1.8%

Rückkaufquote: -0.25%

Mitarbeiter: 59000

Umsatz/Mitarb.: 0.29 Mio. EUR

Analysten:

Analystenrating: Strong buy

Kursziel: 39.48%

Bewertung:

KGV: 38.52

KGV lG: 21.46

KUV: 5.63

KBV: 4.57

PEG-Ratio: 0.7

EV/EBITDA: 22.65

Rentabilität:

Bruttomarge: 65.04%

Gewinnmarge: 14.44%

Operative Marge: 20.28%

Managementeffizenz:

Gesamtkaprendite: 6.98%

Eigenkaprendite: 12.6%

>Anleihen

>Peer Group

Gesundheit, Nierenerkrankungen & -behandlung, Medizinprodukte & -technik/ Implantate/ Wundpflege, Onkologie/ Krebs- Behandlung

>Chart & Kurs - NYSE

>Alle News

03.03.26 - 16:18	Boston Scientific skizziert Wachstumspläne auf der TD Cowen Konferenz (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

03.03.26 - 13:00	The Zacks Analyst Blog Highlights Apple, TotalEnergies, Boston Scientific and Good Times Restaurants (Zacks)
	AAPL, TTE and BSX anchor top analyst picks as Apple eyes double-digit sales growth and Boston Scientific posts 16% organic gains....

28.02.26 - 01:45	Boston Scientific (BSX) Ascends While Market Falls: Some Facts to Note (Zacks)
	The latest trading day saw Boston Scientific (BSX) settling at $76.85, representing a +1.45% change from its previous close....

26.02.26 - 21:06	Boston Scientific Halts Use Of Select Stent Delivery Devices After Patient Deaths (Benzinga)
	Boston Scientific removes certain AXIOS stents after deployment issues linked to 167 injuries and three deaths, FDA says. Importance Rank: 1 read more...

26.02.26 - 21:03	INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Boston Scientific Corporation - BSX (PR Newswire)
	NEW YORK, Feb. 26, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Boston Scientific Corporation ("Boston Scientific" or the "Company") (NYSE: BSX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.......

26.02.26 - 10:30	Is Boston Scientific Stock Underperforming the Dow? (Barchart)
	Um den gesamten Artikel unter newsbreak.com zu lesen, klicken Sie bitte auf die Überschrift...

20.02.26 - 16:45	BSX vs. ABT: Which MedTech Stock is the Better Investment Now? (Zacks)
	Abbott edges out Boston Scientific in the MedTech faceoff, with valuation appeal, strong CGM momentum and strategic deals boosting its investment case....

13.02.26 - 15:15	BSX Posts Q4 Earnings: Should You Buy, Sell or Hold the Stock? (Zacks)
	Boston Scientific tops Q4 estimates, but shares sink on supply woes and EP losses. Can strong growth drivers fuel a 2026 rebound?...

13.02.26 - 14:03	Boston Scientific to participate in TD Cowen′s 46th Annual Health Care Conference (PR Newswire)
	MARLBOROUGH, Mass., Feb. 13, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in TD Cowen's 46th Annual Health Care Conference on Tuesday, March 3, 2026. Mike Mahoney, chairman and chief executive officer, and Kenneth Stein, M.D., senior vice president and......

06.02.26 - 21:24	Boston Scientific′s Worst Day in 25 Years Surprised Analysts (Bloomberg)
	Few analysts foresaw the disappointing results and profit forecast that sent Boston Scientific Corp.'s shares plummeting nearly 20% this week. Even fewer have given up on their bullish calls since....

06.02.26 - 14:18

The TAVR Pioneer Bets Everything on One Market as Its Competitor Spreads Risk (24/7 Wall St.)

Edwards Lifesciences (NYSE: EW) and Boston Scientific (NYSE: BSX) both reported strong quarters, but the results reveal fundamentally different strategies in the heart device market. Edwards doubled down on transcatheter valve replacement with $1.15 billion in TAVR sales, up 12.4%, while Boston Scientific exited TAVR entirely and leaned into its diversified cardiovascular platform. One Specialist, ... The TAVR Pioneer Bets Everything on One Market as Its Competitor Spreads Risk The post The TAVR Pioneer Bets Everything on One Market as Its Competitor Spreads Risk appeared first on 24/7 Wall St.....

05.02.26 - 17:57	Boston Scientific Analyst Slashes Price Target On Disappointing 2026 Outlook (Benzinga)
	Boston Scientific beats Q4 estimates but gives disappointing 2026 guidance, with slowing organic growth and lowered price target. Latest Ratings for BSX DateFirmActionFromTo Feb 2022Morgan StanleyMaintainsOverweight Feb 2022Raymond JamesMaintainsStrong Buy Feb 2022SVB LeerinkMaintainsMarket Perform View More Analyst Ratings for BSX View the Latest Analyst Ratings Importance Rank: 1 read more...

05.02.26 - 14:33	Boston Scientific Analysts Cut Their Forecasts Following Q4 Results (Benzinga)
	Latest Ratings for BSX DateFirmActionFromTo Feb 2022Morgan StanleyMaintainsOverweight Feb 2022Raymond JamesMaintainsStrong Buy Feb 2022SVB LeerinkMaintainsMarket Perform View More Analyst Ratings for BSX View the Latest Analyst Ratings Importance Rank: 1 read more...

04.02.26 - 23:48	Stock Market Today, Feb. 4: Boston Scientific Plunges After Cautious 2026 Guidance Disappoints Investors (Fool)
	Today, Feb. 4, 2026, investors are weighing Boston Scientific's guidance against new deals and its long-term margin path....

04.02.26 - 21:33	Boston Scientific outlines 10% to 11% organic growth target for 2026 amid continued strength in EP and WATCHMAN (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

04.02.26 - 19:24	Why Boston Scientific Stock Plummeted Today (Fool)
	I'll be keeping a close eye on Boston Scientific stock following the market's peculiar reaction to its solid earnings report....

04.02.26 - 19:24	Boston Scientific (BSX) Earnings Transcript (Fool)
	Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...

04.02.26 - 16:45	Boston Scientific (BSX) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
	While the top- and bottom-line numbers for Boston Scientific (BSX) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values....

04.02.26 - 15:31	Trotz Gewinnplus: Aktie von Boston Scientific fällt vorbörslich deutlich (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

04.02.26 - 15:24	Boston Scientific Profit, Sales Rise but Issues Soft Guidance (WSJ EN)
	Sales rose 16%, but the medical-device maker issued a soft forecast for the year, sending shares down premarket....

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Wer ein blindes Pferd verkaufen will, lobt die Füße. - Bauernregel - Bauernweisheit

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram